Goldman Sachs Group, Inc. (The) restated their neutral rating on shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) in a research report report published on Friday. The firm currently has a $20.00 price target on the biotechnology company’s stock.

Several other brokerages have also issued reports on ATRA. Canaccord Genuity reaffirmed a buy rating and set a $47.00 price target on shares of Atara Biotherapeutics in a report on Monday, September 11th. ValuEngine raised shares of Atara Biotherapeutics from a strong sell rating to a sell rating in a report on Friday, September 1st. Zacks Investment Research lowered shares of Atara Biotherapeutics from a buy rating to a hold rating in a report on Monday, August 28th. Jefferies Group LLC reissued a buy rating and set a $30.00 target price on shares of Atara Biotherapeutics in a report on Thursday, August 31st. Finally, BidaskClub lowered shares of Atara Biotherapeutics from a hold rating to a sell rating in a report on Tuesday, August 22nd. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $24.40.

Shares of Atara Biotherapeutics (NASDAQ ATRA) traded down 4.42% during trading on Friday, hitting $16.20. 198,994 shares of the stock were exchanged. The firm has a 50 day moving average price of $15.35 and a 200 day moving average price of $15.62. Atara Biotherapeutics has a 52 week low of $11.80 and a 52 week high of $23.00. The firm’s market capitalization is $495.06 million.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.05). Analysts forecast that Atara Biotherapeutics will post ($3.89) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/atara-biotherapeutics-inc-atra-given-neutral-rating-at-goldman-sachs-group-inc-the/1616086.html.

In other Atara Biotherapeutics news, EVP Christopher Haqq sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $14.92, for a total transaction of $89,520.00. Following the sale, the executive vice president now directly owns 362,080 shares of the company’s stock, valued at approximately $5,402,233.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Isaac E. Ciechanover sold 4,400 shares of the business’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $15.54, for a total transaction of $68,376.00. Following the sale, the chief executive officer now directly owns 737,767 shares in the company, valued at $11,464,899.18. The disclosure for this sale can be found here. Insiders have sold a total of 53,909 shares of company stock worth $810,518 over the last three months. Insiders own 16.20% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. The Manufacturers Life Insurance Company grew its holdings in Atara Biotherapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after acquiring an additional 1,369 shares during the last quarter. Voya Investment Management LLC grew its holdings in Atara Biotherapeutics by 16.2% during the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 1,651 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Atara Biotherapeutics by 2.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock worth $304,000 after purchasing an additional 610 shares during the period. Parametric Portfolio Associates LLC lifted its position in shares of Atara Biotherapeutics by 16.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 29,682 shares of the biotechnology company’s stock worth $416,000 after purchasing an additional 4,293 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Atara Biotherapeutics by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock worth $11,842,000 after purchasing an additional 13,952 shares during the period. 82.95% of the stock is currently owned by hedge funds and other institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.